Am J Psychiatry 162:130-136, January 2005
© 2005 American Psychiatric Association
Clozapine Augmented With Risperidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Richard C. Josiassen, Ph.D.,
Ashok Joseph, M.D.,
Eva Kohegyi, M.D.,
Sudhir Stokes, M.D.,
Mahmood Dadvand, M.D.,
Wynn Wynn Paing, M.D., and
Rita A. Shaughnessy, M.D., Ph.D.
OBJECTIVE: The authors evaluated the efficacy and safety of augmenting clozapine with risperidone in patients with treatment-resistant schizophrenia. METHOD: In a randomized, double-blind, placebo-controlled 12-week trial, 40 patients unresponsive or partially responsive to clozapine monotherapy received a steady dose of clozapine combined with either placebo (N=20) or up to 6 mg/day of risperidone (N=20). Patient psychopathology was assessed at 2-week intervals with the Brief Psychiatric Rating Scale (BPRS) and the Scale for the Assessment of Negative Symptoms (SANS), among other measures. Movement disorders were assessed with the Simpson-Angus Rating Scale. RESULTS: From baseline to week 6 and week 12, mean BPRS total and positive symptom subscale scores were reduced significantly in both groups, but the reductions were significantly greater with clozapine/risperidone treatment. Reductions in SANS scores were also significantly greater with clozapine/risperidone treatment than with clozapine/placebo. The adverse event profile for clozapine/risperidone treatment was similar to that for clozapine/placebo. Simpson-Angus Rating Scale scores were lower with clozapine/risperidone treatment throughout the trial but increased to approach those of clozapine/placebo treatment at week 12. Clozapine/risperidone treatment did not induce additional weight gain, agranulocytosis, or seizures compared with clozapine/placebo treatment. CONCLUSIONS: In patients with a suboptimal response to clozapine, the addition of risperidone improved overall symptoms and positive and negative symptoms of schizophrenia. The combination appears to be safe and well tolerated. Augmentation of clozapine with risperidone may provide additional clinical benefit for patients who are nonresponsive or only partially responsive to clozapine alone.
This article has been cited by other articles:
|
|
|
|
 
A. J Wheeler
Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand
Ann. Pharmacother.,
June 1, 2008;
42(6):
852 - 860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Barbui, A. Signoretti, S. Mule, M. Boso, and A. Cipriani
Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?
Schizophr Bull,
April 23, 2008;
(2008)
sbn030v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. U. Correll, C. Rummel-Kluge, C. Corves, J. M. Kane, and S. Leucht
Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials
Schizophr Bull,
April 21, 2008;
(2008)
sbn018v2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson
Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
Focus,
January 1, 2008;
6(2):
212 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson
Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
Psychiatr Serv,
July 1, 2007;
58(7):
983 - 990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Kreyenbuhl, M. Valenstein, J. F. McCarthy, D. Ganoczy, and F. C. Blow
Long-Term Antipsychotic Polypharmacy in the VA Health System: Patient Characteristics and Treatment Patterns
Psychiatr Serv,
April 1, 2007;
58(4):
489 - 495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ziegenbein and I. T. Calliess
Clozapine and Ziprasidone: A Useful Combination in Patients With Treatment-Resistant Schizophrenia
J Neuropsychiatry Clin Neurosci,
May 1, 2006;
18(2):
246 - 247.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Honer, A. E. Thornton, E. Y.H. Chen, R. C.K. Chan, J. O.Y. Wong, A. Bergmann, P. Falkai, E. Pomarol-Clotet, P. J. McKenna, E. Stip, et al.
Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia
N. Engl. J. Med.,
February 2, 2006;
354(5):
472 - 482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Davis
The Choice of Drugs for Schizophrenia
N. Engl. J. Med.,
February 2, 2006;
354(5):
518 - 520.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Stahl and M. M. Grady
High-Cost Use of Second-Generation Antipsychotics Under California's Medicaid Program
Psychiatr Serv,
January 1, 2006;
57(1):
127 - 129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M Tapp, A. E. Wood, N. Kilzieh, A. Kennedy, and M. A Raskind
Antipsychotic polypharmacy: do benefits justify the risks?
Ann. Pharmacother.,
October 1, 2005;
39(10):
1759 - 1760.
[Full Text]
[PDF]
|
|
|
|
|
|
|
How Effective Is Risperidone Augmentation of Clozapine for Refractory Schizophrenia?
Journal Watch Psychiatry,
January 27, 2005;
2005(127):
6 - 6.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2005
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
